Stopmigren (sumatriptan) coated tablets 100 mg. №3

Description

Stopmigren (sumatriptan) coated tablets 100 mg. №3

Composition

active substance: sumatriptan;

• 50 mg tablets: 1 tablet contains 70 mg of sumatriptan succinate, which is equivalent to 50 mg of sumatriptan;
  excipients: lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; talc; colloidal anhydrous silica;
  shell: mixture for film coating Opadry II Pink (aluminum lacquers magic red (E 129) and indigo carmine (E 132); hypromellose; lactose, monohydrate; triacetin; polyethylene glycol; titanium dioxide (E 171));
• tablets of 100 mg: 1 tablet contains sumatriptan succinate 140 mg, which is equivalent to sumatriptan 100 mg;
  excipients: lactose monohydrate; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; talc; colloidal anhydrous silica;
  shell: Opadry II Orange film coating compound (aluminum varnishes yellow FCF (E 110) and indigo carmine (E 132); hypromellose; lactose, monohydrate; triacetin; polyethylene glycol; iron oxide yellow (E 172); titanium dioxide (E 171) ).

Dosage form

Film-coated tablets.

Basic physical and chemical properties:

• 50 mg tablets: round tablets with a biconvex surface, coated with a pink film coating;
• 100 mg tablets: Round tablets with a biconvex surface, coated with an orange film coating.

Pharmacotherapeutic group

Drugs used to treat migraines. Selective agonist of 5HT1 serotonin receptors. Sumatriptan.
ATC code N02C C01.

Pharmacological properties

Antimigraine pharmaceutical drug. Its use helps to stop or weaken a migraine attack, as well as to eliminate photophobia (photophobia) and nausea associated with a migraine attack. When using this medication, there is a selective narrowing of the vessels of the carotid artery system dilated during a migraine attack. At the same time, taking this drug does not affect cerebral blood flow.

Indications

The medicine Stopmigraine is used to relieve migraine attacks with or without aura.

Contraindications

Stopmigraine is prohibited in case of hypersensitivity to it, stroke (also suffered), ischemic heart disease, severe hepatic / renal failure, occlusive peripheral vascular disease, uncontrolled arterial hypertension, transient cerebrovascular accident (including in the past).
The simultaneous use of Stopmigraine and drugs that contain ergotamine or its derivatives is prohibited. Stopmigren should not be used simultaneously with monoamine oxidase inhibitors and within fourteen days after their cancellation.
Stopmigraine is not used in patients under eighteen and over sixty-five years of age.

Application during pregnancy and lactation

During these periods, the anti-migraine drug Stopmigren is contraindicated.

Method of administration and dosage

Stopmigren tablets should not be used to prevent seizures.

The recommended dose of Stopmigren should not be exceeded.

Stopmigren tablets is recommended to be used as early as possible after the onset of a migraine attack, although it is equally effective at each stage.

The recommended dose of Stopmigren for adults is 50 mg. In some cases, the dose can be increased to 100 mg.

If the dose of the drug is ineffective, you do not need to use another dose during the same attack. The next dose of Stopmigren can be used during subsequent attacks.

If the patient responds to the first dose but the symptoms return, the second dose can be used within the next 24 hours, the minimum interval between these doses should be at least 2 hours. The total daily dose for any 24 hours should not exceed 300 mg.

The Stopmigren tablets should be swallowed whole with water.

Elderly patients (over 65 years).

Experience with sumatriptan in patients over 65 years of age is insufficient. Although the pharmacokinetics of the drug do not differ from those in younger people, until additional clinical data are available, the use of Stopmigren in elderly patients is not recommended.

Children

It is not recommended, as the efficacy and safety of sumatriptan in children and adolescents have not been established.

Overdose

In case of an overdose with Stopmigren, there is an increase in the side effects of this pharmaceutical.
In case of overdose, observation of the patient is required for at least ten hours; if necessary, symptomatic therapy is indicated. There is no specific antidote.

Side effects

Side effects that may develop as a result of the use of the pharmaceutical drug Stopmigren may be as follows: arterial hypotension, nausea, tachycardia / bradycardia, transient hypertension, spasm of the coronary (cardiac) arteries, vomiting, palpitations, abdominal discomfort, weakness, dizziness, drowsiness, drowsiness (double vision), seizures (rare), nystagmus, decreased visual acuity, scotoma (loss of the area of ​​vision), skin reactions (skin rash, itching, urticaria, erythema), sensations of heat and tingling, anaphylaxis (very rare), sensation severity, flushing, myalgia (muscle pain).